uniQure (NASDAQ:QURE) Short Interest Down 21.2% in December

uniQure (NASDAQ:QURE) was the recipient of a significant decline in short interest during the month of December. As of December 31st, there was short interest totalling 3,390,000 shares, a decline of 21.2% from the December 15th total of 4,300,000 shares. Based on an average daily volume of 2,100,000 shares, the short-interest ratio is presently 1.6 days.

Analyst Ratings Changes

QURE has been the topic of a number of analyst reports. Raymond James upgraded shares of uniQure from an “outperform” rating to a “strong-buy” rating and lifted their target price for the stock from $20.00 to $52.00 in a research report on Tuesday, December 10th. HC Wainwright reissued a “buy” rating and issued a $25.00 target price on shares of uniQure in a research note on Tuesday, December 10th. Royal Bank of Canada lifted their price target on uniQure from $14.00 to $20.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 11th. Stifel Nicolaus increased their price objective on uniQure from $12.00 to $32.00 and gave the company a “buy” rating in a research note on Monday, December 16th. Finally, Wells Fargo & Company raised shares of uniQure from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, December 10th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $33.88.

uniQure Trading Down 1.1 %

NASDAQ QURE traded down $0.16 during trading on Friday, hitting $14.05. The company had a trading volume of 994,420 shares, compared to its average volume of 1,365,092. The company’s fifty day moving average is $12.09 and its 200-day moving average is $8.35. The company has a market cap of $684.80 million, a price-to-earnings ratio of -2.83 and a beta of 0.41. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92. uniQure has a one year low of $3.73 and a one year high of $19.18.

uniQure (NASDAQ:QURE) last posted its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share for the quarter, beating the consensus estimate of ($1.12) by $0.21. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. The business had revenue of $2.29 million for the quarter, compared to analysts’ expectations of $2.73 million. On average, sell-side analysts predict that uniQure will post -3.74 earnings per share for the current year.

Insiders Place Their Bets

In other uniQure news, CEO Matthew C. Kapusta sold 3,418 shares of uniQure stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $7.63, for a total transaction of $26,079.34. Following the transaction, the chief executive officer now directly owns 597,915 shares of the company’s stock, valued at approximately $4,562,091.45. This trade represents a 0.57 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 4.74% of the company’s stock.

Hedge Funds Weigh In On uniQure

A number of institutional investors have recently added to or reduced their stakes in the company. Point72 Asset Management L.P. increased its stake in shares of uniQure by 336.1% in the 3rd quarter. Point72 Asset Management L.P. now owns 976,893 shares of the biotechnology company’s stock worth $4,816,000 after acquiring an additional 752,889 shares in the last quarter. Walleye Capital LLC bought a new position in shares of uniQure during the third quarter valued at approximately $444,000. FMR LLC lifted its holdings in shares of uniQure by 8,056.6% during the third quarter. FMR LLC now owns 350,572 shares of the biotechnology company’s stock valued at $1,728,000 after purchasing an additional 346,274 shares during the last quarter. Y Intercept Hong Kong Ltd bought a new stake in shares of uniQure in the 3rd quarter worth approximately $283,000. Finally, Franklin Resources Inc. purchased a new stake in shares of uniQure in the 3rd quarter worth approximately $7,360,000. Institutional investors own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.